

1 800 CONTACTS INC
Form 10-Q
November 10, 2005

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 10-Q

(Mark one)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended October 1, 2005

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____ .

Commission file number: 0-23633

1-800 CONTACTS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

87-0571643
(I.R.S. Employer Identification No.)

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

**66 E. Wadsworth Park Drive,
Draper, UT**
(Address of principal executive offices)

84020
(Zip Code)

(801) 924-9800
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to the filing requirements for at least the past 90 days.

Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange act).

Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange act).

Yes No

As of November 7, 2005, the Registrant had 13,339,557 shares of Common Stock, par value \$0.01 per share, outstanding.

1-800 CONTACTS, INC.

INDEX

PART I. FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Financial Statements</u> <u>Condensed Consolidated Balance Sheets as of January 1, 2005</u> <u>and October 1, 2005</u> <u>Condensed Consolidated Statements of Operations for the Quarter and Three Quarters</u> <u>Ended</u> <u>October 2, 2004 and October 1, 2005</u> <u>Condensed Consolidated Statements of Cash Flows for the Three Quarters Ended</u> <u>October 2, 2004 and October 1, 2005</u> <u>Notes to Condensed Consolidated Financial Statements</u>
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>
<u>Item 4.</u>	<u>Controls and Procedures</u>

PART II. OTHER INFORMATION

<u>Item 1.</u>	<u>Legal Proceedings.</u>
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>
<u>Item 4.</u>	<u>Submission of Matters to a Vote of Security Holders</u>
<u>Item 5.</u>	<u>Other Information</u>
<u>Item 6.</u>	<u>Exhibits</u>

PART 1. FINANCIAL INFORMATION**Item 1. Financial Statements****1-800 CONTACTS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(in thousands)****(unaudited)****ASSETS**

	January 1, 2005	October 1, 2005
CURRENT ASSETS:		
Cash	\$ 3,105	\$ 226
Accounts receivable, net	3,178	4,247
Other receivables	2,398	2,083
Inventories, net	22,206	27,963
Deferred income taxes	1,328	1,402
Other current assets	1,546	2,541
Total current assets	33,761	38,462
PROPERTY AND EQUIPMENT, net	20,618	25,173
DEFERRED INCOME TAXES	720	908
GOODWILL	34,320	35,223
DEFINITE-LIVED INTANGIBLES, net	17,897	14,864
OTHER ASSETS	1,669	3,398
Total assets	\$ 108,985	\$ 118,028

LIABILITIES AND STOCKHOLDERS EQUITY

CURRENT LIABILITIES:		
Current portion of long-term debt	\$ 1,632	\$ 1,603
Current portion of capital lease obligations	47	43
Income taxes payable	1,560	171
Accounts payable	9,762	17,386
Accrued liabilities	7,303	10,065
Unearned revenue	3,500	2,036
Total current liabilities	23,804	31,304
LONG-TERM LIABILITIES:		
Line of credit	14,404	19,449
Long-term debt, net of current portion	8,170	6,742
Capital lease obligations, net of current portion	98	60
Deferred income tax liabilities	1,458	188
Unearned revenue, net of current portion	1,667	
Other long-term liabilities	880	736
Total long-term liabilities	26,677	27,175
STOCKHOLDERS EQUITY		
Common stock, 13,299 and 13,340 issued and outstanding, respectively	133	133

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

Additional paid-in capital	46,061	48,505
Deferred compensation on restricted stock grants	(103)	(666)
Retained earnings	12,218	11,868
Accumulated other comprehensive income (loss)	195	(291)
Total stockholders' equity	58,504	59,549
Total liabilities and stockholders' equity	\$ 108,985	\$ 118,028

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

	Quarter Ended		Three Quarters Ended	
	October 2, 2004	October 1, 2005	October 2, 2004	October 1, 2005
NET SALES	\$ 56,893	\$ 60,858	\$ 157,713	\$ 182,506
COST OF GOODS SOLD	34,889	37,706	97,140	113,178
Gross profit	22,004	23,152	60,573	69,328
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES:				
Advertising	6,533	6,606	22,572	20,264
Legal and professional	1,026	1,210	4,207	3,400
Research and development	567	426	1,902	2,292
Purchased in-process research and development			83	
Other selling, general and administrative	10,789	13,538	31,437	37,359
Total selling, general and administrative expenses	18,915	21,780	60,201	63,315
INCOME FROM OPERATIONS	3,089	1,372	372	6,013
OTHER EXPENSE, net	(216)	(755)	(1,271)	(2,562)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	2,873	617	(899)	3,451
PROVISION FOR INCOME TAXES	(1,520)	(1,191)	(1,102)	(3,801)
NET INCOME (LOSS)	\$ 1,353	\$ (574)	\$ (2,001)	\$ (350)
PER SHARE INFORMATION:				
Basic and diluted net income (loss) per common share	\$ 0.10	\$ (0.04)	\$ (0.15)	\$ (0.03)

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Three Quarters Ended	
	October 2, 2004	October 1, 2005
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (2,001)	\$ (350)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	5,630	6,572
Amortization of debt issuance costs and discounts	247	138
Foreign currency exchange loss	27	1,390
Stock-based compensation	8	79
Purchased in-process research and development	83	
Loss on disposal of property and equipment	89	519
Deferred income taxes, net of effects of acquisition	(1,439)	(1,463)
Changes in operating assets and liabilities, net of effects of acquisition:		
Accounts receivable, net	(671)	(1,193)
Inventories, net	695	(6,025)
Other receivables	(1,443)	315
Other current assets	333	(1,047)
Income taxes payable	2,170	(1,245)
Accounts payable	(1,621)	5,917
Accrued liabilities	3,014	4,656
Unearned revenue	(158)	(3,110)
Net cash provided by operating activities	4,963	5,153
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property and equipment	(5,996)	(9,549)
Proceeds from sale of property and equipment	3	27
Purchase of definite-lived intangible assets	(3,997)	(610)
Cash paid for acquisition of VisionTec	(3,776)	
Deposits and other	(289)	(2,121)
Net cash used in investing activities	\$ (14,055)	\$ (12,253)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from exercise of common stock options	\$ 159	\$ 381
Net borrowings on line of credit	16,351	5,045
Principal payments on capital lease obligations	(219)	(35)
Debt issuance costs	(196)	
Principal payments on long-term debt	(8,511)	(1,261)
Proceeds from international government grant	873	
Net cash provided by financing activities	8,457	4,130
EFFECT OF FOREIGN EXCHANGE RATES ON CASH	(67)	91
NET DECREASE IN CASH	(702)	(2,879)
CASH AT BEGINNING OF PERIOD	1,075	3,105
CASH AT END OF PERIOD	\$ 373	\$ 226
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for interest	\$ 964	\$ 807
Cash paid for income taxes	370	6,510

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:

During the first quarter of 2004, the Company purchased the stock of VisionTec (subsequently renamed ClearLab UK, Ltd.). The purchase consideration included cash of \$3,776 and common stock with a fair value of \$3,200.

As part of the acquisition of ClearLab International in 2002, the Company entered into an agreement to issue 270,000 options to purchase shares of 1-800 CONTACTS, INC. common stock in three equal tranches. The first tranche of 90,000 options vested on July 24, 2005. The Company used the Black-Scholes option-pricing model to determine the fair-value of these options, as of the vesting date. Using this method, the vested options were valued at approximately \$1.3 million and the Company recorded this amount as additional purchase consideration, increasing goodwill.

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1. PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments), which in the opinion of management, are necessary to present fairly the results of operations of the Company for the periods presented. It is suggested that these condensed consolidated financial statements be read in conjunction with the audited financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended January 1, 2005.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

NOTE 2. INVENTORIES

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

Inventories are recorded at the lower of cost (using the first-in, first-out method) or market value. Elements of cost in the Company's manufactured inventories generally include raw materials, direct labor, manufacturing overhead and freight-in. Inventories consisted of the following (in thousands):

	January 1, 2005	October 1, 2005
Purchased contact lenses and accessories	\$ 16,216	\$ 19,789
Manufactured inventories:		
Raw materials	930	1,343
Work in process	1,796	1,878
Finished goods contact lenses	3,264	4,953
Total	\$ 22,206	\$ 27,963

Provision is made to reduce excess and obsolete inventories to their estimated net realizable values. As of January 1, 2005 and October 1, 2005, reserves for excess and obsolete inventories were approximately \$1.2 million and \$1.0 million, respectively.

NOTE 3. NET INCOME (LOSS) PER COMMON SHARE

Basic net income (loss) per common share (Basic EPS) excludes dilution and is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share (Diluted EPS) reflects the potential dilution that could occur if stock options or other common stock equivalents were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an antidilutive effect on net income (loss) per common share. For the quarter and three quarters ended October 1, 2005, options to purchase 1,278,569 and 974,339 shares of common stock, respectively, were not included in the computation of Diluted EPS because the effect would be antidilutive. For the quarter and three quarters ended October 2, 2004, options to purchase 956,071

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

and 1,257,476 shares of common stock, respectively, were not included in the computation of Diluted EPS because the effect would be antidilutive.

The following is a reconciliation of the numerator and denominator used to calculate Basic and Diluted EPS (in thousands, except per share amounts):

	Quarter Ended October 2, 2004			Quarter Ended October 1, 2005		
	Net Income	Shares	Per-Share Amount	Net Loss	Shares	Per-Share Amount
Basic EPS	\$ 1,353	13,287	\$ 0.10	\$ (574)	13,329	\$ (0.04)
Effect of stock options		86				
Diluted EPS	\$ 1,353	13,373	\$ 0.10	\$ (574)	13,329	\$ (0.04)

	Three Quarters Ended October 2, 2004			Three Quarters Ended October 1, 2005		
	Net Loss	Shares	Per-Share Amount	Net Loss	Shares	Per-Share Amount
Basic EPS	\$ (2,001)	13,254	\$ (0.15)	\$ (350)	13,315	\$ (0.03)
Effect of stock options						
Diluted EPS	\$ (2,001)	13,254	\$ (0.15)	\$ (350)	13,315	\$ (0.03)

NOTE 4. COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) for the quarter and three quarters ended October 2, 2004 and October 1, 2005 consists of the following components (in thousands):

	Quarter Ended		Three Quarters Ended	
	October 2, 2004	October 1, 2005	October 2, 2004	October 1, 2005
Net income (loss)	\$ 1,353	\$ (574)	\$ (2,001)	\$ (350)
Foreign currency translation	45	(127)	(125)	(487)
Comprehensive income (loss)	\$ 1,398	\$ (701)	\$ (2,126)	\$ (837)

The foreign currency translation gain (loss) results primarily from changes in exchange rates relative to the U.S. dollar from the translation of the Company's Singapore and United Kingdom subsidiaries' financial statements.

NOTE 5. STOCK-BASED COMPENSATION

The Company applies Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations and uses the intrinsic method of accounting for its stock option grants to employees and directors. No compensation expense has been recognized for stock option awards granted at or above fair market value of the stock on the date of grant.

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, and SFAS No. 148, Accounting for Stock-Based Compensation Transition and Disclosure, established accounting and disclosure requirements using a fair-value based method of accounting for stock-based employee compensation plans. As permitted by existing accounting standards, the Company has elected to continue to apply the intrinsic-value-based method of accounting described above, and has adopted only the disclosure requirements of SFAS No. 123.

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

If compensation expense for all stock options had been determined consistent with SFAS No. 123, the Company's net income (loss) and basic and diluted net income (loss) per common share would have been as follows (in thousands, except per share amounts):

	Quarter Ended	
	October 2, 2004	October 1, 2005
Net income (loss):		
As reported	\$ 1,353	\$ (574)
Fair-value based compensation, net of tax	(380)	(155)
Pro forma	\$ 973	\$ (729)
Basic and diluted net income(loss) per common share:		
As reported	\$ 0.10	\$ (0.04)
Pro forma	\$ 0.07	\$ (0.05)

	Three Quarters Ended	
	October 2, 2004	October 1, 2005
Net loss:		
As reported	\$ (2,001)	\$ (350)
Fair-value based compensation, net of tax	(1,208)	(727)
Pro forma	\$ (3,209)	\$ (1,077)
Basic and diluted net loss per common share:		
As reported	\$ (0.15)	\$ (0.03)
Pro forma	\$ (0.24)	\$ (0.08)

The weighted average per share fair value of options granted during the quarter ended October 2, 2004 and the three quarters ended October 2, 2004 was \$6.77 and \$11.69, respectively. No options were granted during the quarter ended October 1, 2005. The weighted average per share fair value of options granted during the three quarters ended October 1, 2005 was \$11.30. The fair value of each option grant has been estimated on the grant date using the Black-Scholes option-pricing model with the following weighted average assumptions:

	Quarter Ended		Three Quarters Ended	
	October 2, 2004	October 1, 2005	October 2, 2004	October 1, 2005
Risk-free interest rate	3.6%		3.2%	3.7%
Expected dividend yield	0.0%		0.0%	0.0%
Volatility	65.9%		67.6%	65.5%
Expected life	5 years		5 years	5 years

NOTE 6. RECENT TRANSACTIONS AND AGREEMENTS

Japanese License and Royalty Agreement

On December 15, 2004 the Company signed an agreement which grants Menicon Co., Ltd. (Menicon) exclusive rights to develop, manufacture and market certain disposable contact lenses and related intellectual property in Japan.

Under the terms of the agreement, Menicon licenses from the Company different types of intellectual property, including contact lens material, manufacturing technology and related knowledge. In consideration, Menicon is expected to pay nonrefundable license fees of \$18 million, of which \$5 million was paid in December 2004 upon signing the agreement. The remaining \$13 million is expected to be paid over the next three to five years as the

Company fulfills its obligations and as corresponding milestones relating to Japanese regulatory approval and Menicon's launch of the product in the Japanese market are met. Of the total \$18 million license fee, \$10 million is guaranteed.

The Company evaluated the agreement under Emerging Issues Task Force 00-21, Revenue Arrangements with Multiple Deliverables, and determined that this arrangement should be considered a single unit of accounting. Therefore, in applying the principles of Staff Accounting Bulletin No. 104 to the license agreement, the Company considered the terms and conditions of the agreement to arrive at a proportional performance methodology of recognizing revenue. Accordingly, the Company is recognizing the guaranteed portion of the license fees from this agreement on a straight-line basis, limited by the amount of cash received, over the period of the Company's continued involvement in meeting its obligations, estimated to be through June of 2007. In the event the Company achieves a milestone (not relating to the guaranteed portion of the license fees) prior to the completion of its obligations under the agreement, the milestone payment will be recognized on a straight-line basis over the remaining period of the Company's continued involvement in meeting its obligations. Upon completion of this agreement, the Company will recognize the remaining milestone payments as the agreed upon milestones are achieved. The Company recorded income of \$1.0 million and \$3.0 million for the fiscal quarter and three quarters ended October 1, 2005, respectively.

If Menicon has not received regulatory approval on or before December 31, 2009, it may return all intellectual property covered by the agreement and in-process regulatory approvals to the Company, and the Company may pursue the Japanese market on its own and terminate the exclusive agreement.

Under the terms of the agreement, Menicon will also pay royalties for a period of at least 15 years from the product launch date in Japan on contact lenses sold that were manufactured using the licensed technology, with a guaranteed minimum of \$5 million per year beginning the earlier of the second year after product launch or 2012. The agreement does not include the sale of any of the Company's current equipment, facilities or capacity and is limited to the Japanese contact lens market.

Optical Retail Store Agreement

During the latter part of 2004, the Company entered into an agreement with a regional optical retail chain in Utah in which the two companies would jointly market and sell contact lenses in Utah. In December 2004, the companies began jointly serving these Utah customers. The agreement is for one year, with one year renewals at the option of both parties.

Under the agreement, the Company fulfills substantially all orders taken at the retail optical chain for contact lenses and both parties share in the operating results of the combined contact lens business based on a certain allocation percentage. However, the Company has guaranteed that the retail chain will receive at least \$0.5 million of annual earnings under the arrangement. Additionally, the Company committed to purchase approximately \$0.3 million per year in inventory from the retail chain's source of supply. Under the arrangement, the Company records gross revenues for all orders fulfilled and records selling, general and administrative expense for the retail chain's share of the net operating results.

NOTE 7. COMMON STOCK TRANSACTIONS

During the three quarters ended October 1, 2005, employees exercised stock options to purchase 39,903 shares of common stock for a total of approximately \$0.4 million. The Company recorded an increase in additional paid-in capital of approximately \$0.1 million as a result of the

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

income tax benefit related to these stock option exercises.

During the three quarters ended October 1, 2005, the Company granted nonqualified stock options to purchase 1,000 shares of common stock to employees of the Company. The exercise price of the options was \$22.00 per share, which was not less than the quoted fair market value at the grant date. The options vest equally over a four-year period and expire in five years.

During the three quarters ended October 1, 2005, the Board of Directors granted 30,000 shares of restricted common stock to three employees of the Company. Two of the grants totaling 20,000 shares were valued at the closing stock price of \$22.67 on March 21, 2005, the date of the grant. The third grant of 10,000 was valued at the closing stock price of \$18.84 on May 2, 2005, the date of the grant. The restrictions on the common stock lapse in equal amounts over a five-year period. The Company recorded expense of approximately \$35,000 and \$79,000 related to restricted stock during the quarter ended and three quarters ended October 1, 2005, respectively. As of October 1, 2005 approximately \$0.7 million has been deferred and will be recognized over the vesting period.

As part of the acquisition of ClearLab International in 2002, the Company entered into an agreement to issue 270,000 options to purchase shares of 1-800 CONTACTS, INC. common stock in three equal tranches. The three tranches of 90,000 options vest on July 24, 2005, 2006 and 2007, respectively. The first tranche of 90,000 options vested on during the third fiscal quarter ended October 1, 2005. The Company used the Black-Scholes option-pricing model to determine the fair-value of these options, as of the vesting date. Using this method, these vested options were valued at approximately \$1.3 million and the Company recorded this amount as additional purchase consideration, increasing goodwill. Goodwill associated with the ClearLab International acquisition amounted to approximately \$12.9 million as of October 1, 2005.

NOTE 8. DEBT OBLIGATIONS

The Company has a loan agreement with a U.S. bank providing for a revolving credit facility for borrowings of up to \$25.6 million as of October 1, 2005, which amount is reduced thereafter on the first day of each September, December, March and June by \$0.4 million until the maturity date of February 27, 2007. Additionally, the agreement provides for letters of credit up to a maximum of \$15 million outstanding or payable at any time. The loan agreement specifies that if the maximum leverage ratio, as defined in the agreement, is greater than 2.5, then the amounts outstanding on the revolving credit facility together with the amount of all outstanding letters of credit can at no time exceed the Company's book value of inventory. As of October 1, 2005, the Company was not subject to this restriction and could borrow up to \$25.6 million. Outstanding borrowings on the revolving credit facility bear interest at a floating rate equal to the lender's prime interest rate plus a margin or the lender's LIBOR rate plus a margin. The interest rate is adjusted quarterly and ranges between prime plus 0.0 percent and prime plus 1.25 percent or between the applicable LIBOR rate plus 2.0 percent and the applicable LIBOR rate plus 3.25 percent, depending on the Company's maximum leverage ratio. As of October 1, 2005, the prime rate margin is 0.0 percent and the LIBOR rate margin is 2.0 percent. Interest is payable monthly. As of October 1, 2005, the Company's outstanding borrowings on the credit facility, including bank overdrafts, were \$19.4 million. Of this amount, \$10.0 million bore interest at the lender's LIBOR rate plus 2.0 percent (5.83% at October 1, 2005) and the remaining \$9.4 million bore interest at the lender's prime rate plus 0.0 percent (6.75% at October 1, 2005). The facility requires the quarterly payment of an unused credit fee which ranges from 0.38 percent to 0.5 percent, depending on the Company's maximum leverage ratio.

All outstanding balances on this credit facility are secured by substantially all of the Company's U.S. assets, subsidiary debt instruments, 100 percent ownership interests in all domestic subsidiaries and 65 percent ownership interests in foreign subsidiaries directly owned by the Company. The loan agreement includes various financial covenants including a capital expenditure limit, a maximum leverage ratio, a minimum working capital requirement, a minimum fixed charge coverage ratio and a minimum net worth requirement. The loan agreement does not permit the Company or its subsidiaries to dissolve, sell, dispose or merge all of their assets or acquire all of the assets of any entity without the written consent of the U.S. bank, unless the transaction meets the definition of a Permitted Acquisition Basket, as defined in the agreement. The loan agreement also places a limit on the amount the Company can loan to any entity, outside the normal course of business. Additionally, the agreement does not permit the Company to declare or pay any cash dividends, to repurchase its stock or to perform other similar equity transactions prior to December 31, 2005; thereafter, such transactions are subject to other terms. This agreement defines several customary events of default including any material adverse change or any event that occurs which may cause a material adverse change in the Company's or its subsidiaries' condition.

As of October 1, 2005, the Company had an unsecured, non-interest bearing note to ClearLab International's chief technology officer with a principal balance of SGD\$1,375,000 (USD\$814,000). The note payable is discounted at 7%. Payments are due in equal monthly installments through July 2007.

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

As of October 1, 2005, the Company had a term loan payable to a Singapore bank with a principal balance of SGD\$6,110,000 (USD\$3,618,000) that bears interest at 6.75% and is secured by substantially all of the assets of ClearLab International. Interest payments are due monthly. Principal payments are due in monthly installments through December 2007. This note also contains various financial covenants including minimums on net worth and shareholders' funds. 1-800 CONTACTS, INC. has guaranteed this term loan.

As of October 1, 2005, the Company also had a note payable to the former parent of ClearLab International with a principal balance of SGD\$6,892,000 (USD\$4,082,000) that bears interest at 6% and has a subordinated position to the term loan payable to the Singapore bank. The note payable is discounted at 7%. Interest payments are due monthly. Principal payments are due in monthly installments from January 2008 through December 2009. 1-800 CONTACTS, INC. has guaranteed this note.

Cross default clauses exist such that if the Company were in default on its U.S. debt, the Company would also be in default on its Singapore debt. If the Company were in default on its Singapore bank term loan, the Company would also be in default on its note payable to the former parent of ClearLab International and its loan agreement with its U.S. bank.

NOTE 9. COMMITMENTS AND CONTINGENCIES

Legal and Regulatory Matters

The sale and delivery of contact lenses are governed by both federal and state laws and regulations, including the federal Fairness to Contact Lens Consumer Act (FCLCA). The FCLCA requires that contact lenses only be sold to consumers based on the seller obtaining a copy of the prescription itself or verifying the prescription by direct communication with the customer's prescriber. Consistent with this requirement, the Company's current operating practice is to require all customers to provide either a valid copy of their prescription or the contact information for their prescriber so that the Company can verify their prescription by direct communication with their prescriber. If the Company does not have a valid copy of the customer's prescription, the Company directly communicates to the customer's prescriber the precise prescription information received from the customer and informs the prescriber that it will proceed with the sale based on this prescription information unless the prescriber advises it within eight business hours that such prescription information is expired or otherwise invalid. If the prescriber properly advises the Company within this time period that the customer's prescription is expired or otherwise invalid, the Company's practice is to cancel the customer's order. On the other hand, if the prescriber either advises the Company that the prescription is valid or fails to respond properly within the required time period, the Company's practice is to complete the sale based on the prescription information communicated to the prescriber, as expressly permitted by the FCLCA. The Company retains copies of the written prescriptions that it receives and maintains records of its communications with the customer's prescriber. The Company believes that it is complying with the regulations of the FCLCA.

On October 13, 2005, the Company received a letter from the Federal Trade Commission (FTC) notifying the Company that the FTC had received numerous complaints from eye care providers about the Company's inbound fax system. Copies of the FTC letter and the Company's response to the FTC are available on the Company's website at www.order.1800contacts.com/compliance. The FTC letter states that the complaints allege that [the Company's] fax lines are often busy, and that prescribers are therefore unavailable to communicate with it regarding verification requests.

In response to this letter from the FTC, the Company conducted a thorough review of its systems and found that its verification fax system (provided by a third party with capacity to receive more than a hundred simultaneous faxes) has maintained 99.96% availability to date in 2005. However, the Company points out in its response to the FTC that with millions of orders processed each year by the Company, even this near perfect uptime could result in instances where a small number of prescribers find the system unavailable for a brief period of time. In order to ensure compliance with the FCLCA, the Company suspends shipping during a verification system outage and does not take advantage of any system outages to reduce the eight business hours available to prescribers to respond to verification requests as required by the FCLCA.

From time to time the Company is involved in legal matters generally incidental to its business. It is the opinion of management, after discussion with legal counsel that, except for legal and professional fees that the Company incurs from time to time, the ultimate dispositions of all of these matters will not have a material impact on the financial position, liquidity or results of operations of the Company. However, there can be no assurance that the Company will be successful in its efforts to satisfactorily resolve these matters, and the ultimate outcome could result in a material negative impact on the Company's financial position, liquidity or results of operations.

Advertising Commitments

As of October 1, 2005, the Company had entered into certain noncancelable commitments with various advertising companies that will require the Company to pay approximately \$2.2 million and \$7.6 million for advertising during the remainder of 2005 and in 2006, respectively.

NOTE 10. SEGMENT INFORMATION

The Company has two operating segments. These operating segments represent components of the Company for which separate financial information is available and are evaluated regularly by management in determination of

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

resource allocation and performance assessment. The Company's U.S. Retail segment includes the operations of 1-800 CONTACTS, a direct marketer of replacement contact lenses. The Company's International segment includes the operations of ClearLab International and ClearLab UK, which are developers, marketers, manufacturers and distributors of contact lenses. The U.S. Retail segment includes revenue from the optical retail store agreement and the International segment includes revenue from the Japanese license and royalty agreement. Operating segment information for the quarter and three quarters ended October 2, 2004 and October 1, 2005 is as follows (in thousands):

Quarter Ended October 2, 2004	U.S. Retail	International	Eliminations	Total
Net sales	\$ 54,966	\$ 1,927	\$	\$ 56,893
Gross profit (loss)	22,235	(231)		22,004
Research and development		567		567
Other selling, general and administrative expense	9,701	1,088		10,789
Income (loss) from operations	\$ 5,179	\$ (2,090)	\$	\$ 3,089

Quarter Ended October 1, 2005	U.S. Retail	International	Eliminations	Total
Net sales (International segment includes intersegment sales of \$917)	\$ 55,791	\$ 5,984	\$ (917)	\$ 60,858
Gross profit	21,928	1,841	(617)	23,152
Research and development		426		426
Other selling, general and administrative expense	10,998	2,540		13,538
Income (loss) from operations	\$ 3,367	\$ (1,378)	\$ (617)	\$ 1,372

Three Quarters Ended October 2, 2004	U.S. Retail	International	Eliminations	Total
Net sales	\$ 153,159	\$ 4,554	\$	\$ 157,713
Gross profit (loss)	60,990	(417)		60,573
Research and development	536	1,366		1,902
Purchased in-process research and development		83		83
Other selling, general and administrative expense	28,276	3,161		31,437
Income (loss) from operations	\$ 5,865	\$ (5,493)	\$	\$ 372

Three Quarters Ended October 1, 2005	U.S. Retail	International	Eliminations	Total
Net sales (International segment includes intersegment sales of \$1,291)	\$ 168,924	\$ 14,873	\$ (1,291)	\$ 182,506
Gross profit	66,972	3,147	(791)	69,328
Research and development		2,292		2,292
Other selling, general and administrative expense	31,870	5,489		37,359
Income (loss) from operations	\$ 12,159	\$ (5,355)	\$ (791)	\$ 6,013

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

The following reconciles total segment income from operations to income (loss) before provision for income taxes for the quarter and three quarters ended October 2, 2004 and October 1, 2005 as follows (in thousands):

	Quarter Ended	
	October 2, 2004	October 1, 2005
Income from operations	\$ 3,089	\$ 1,372
Interest expense	(374)	(347)
Foreign currency exchange transaction gain (loss)	58	(330)
Other income (expense), net	100	(78)
Income before provision for income taxes	\$ 2,873	\$ 617

	Three Quarters Ended	
	October 2, 2004	October 1, 2005
Income from operations	\$ 372	\$ 6,013
Interest expense	(1,176)	(995)
Foreign currency exchange transaction loss	(27)	(1,390)
Other expense, net	(68)	(177)
Income (loss) before provision for income taxes	\$ (899)	\$ 3,451

Identifiable segment assets are as follows (in thousands):

Fiscal Year Ended January 1, 2005	U.S. Retail	International	Total
Long-lived assets, net	\$ 33,374	\$ 39,461	\$ 72,835
Total assets	56,216	52,769	108,985

Quarter Ended October 1, 2005	U.S. Retail	International	Total
Long-lived assets, net	\$ 35,854	\$ 43,712	\$ 79,566
Total assets	59,653	58,375	118,028

NOTE 11. RECENTLY ISSUED ACCOUNTING STANDARDS

In December 2004, the FASB issued SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R), which replaces SFAS No. 123, Accounting for Stock-Based Compensation, (SFAS 123) and supercedes APB Opinion No. 25, Accounting for Stock Issued to Employees. SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values beginning with the first annual period after June 15, 2005, with early adoption encouraged. The pro forma disclosures previously permitted under SFAS 123 will no longer be an alternative to financial statement recognition. The Company is required to adopt SFAS 123R in the first fiscal quarter of 2006, beginning January 1, 2006. Under SFAS 123R, the Company must determine the appropriate fair value model to be used for valuing share-based payments, the amortization method for compensation cost and the transition method to be used at date of adoption. The transition methods include prospective and retroactive adoption options. Under the retroactive option, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The prospective method requires that compensation expense be recorded for all unvested stock options at the beginning of the first quarter of adoption of SFAS 123R, while the retroactive methods would record compensation expense for all unvested stock options and beginning with the first period restated. The Company is evaluating the requirements of SFAS 123R and expects that the adoption of SFAS 123R will have a material adverse impact on its consolidated results of operations and earnings per share. The Company has not yet determined the method of adoption or the effect of adopting SFAS 123R.

In November 2004, the FASB issued SFAS No. 151, *Inventory Costs* (SFAS 151). The provisions of this statement become effective for the Company in fiscal 2006. SFAS 151 amends the existing guidance on the recognition of inventory costs to clarify the accounting for abnormal amounts of idle expense, freight, handling costs, and wasted material (spoilage). Existing rules indicate that under some circumstances, items such as idle facility expense, excessive spoilage, double freight, and rehandling costs may be so abnormal as to require treatment as current period charges. SFAS 151 requires that those items be recognized as current period charges regardless of whether they meet the criterion of so abnormal . In addition, SFAS 151 requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. The Company is required to adopt SFAS 151 in the fiscal year beginning January 1, 2006. The Company has not yet determined the impact of SFAS 151.

In June 2005, the FASB issued SFAS No. 154, *Accounting Changes and Error Corrections* (SFAS 154) a replacement of APB Opinion No. 20, *Accounting Changes*, and SFAS No. 3, *Reporting Accounting Changes in Interim Financial Statements*. Under the provisions of SFAS No. 154, voluntary changes in accounting principles are applied retrospectively to prior periods financial statements unless it would be impractical. SFAS No. 154 supersedes APB Opinion No. 20, which required that most voluntary changes in accounting principles be recognized by including in the current period s net income the cumulative effect of the change. SFAS No. 154 also makes a distinction between retrospective application of a change in accounting principle and the restatement of financial statements to reflect the correction of an error. The provisions of SFAS No. 154 are effective for accounting changes made in fiscal years beginning after December 15, 2005. The Company does not expect adoption to have a material impact on the consolidated financial statements, results of operations or liquidity of the Company.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

The Company is a leading direct marketer of replacement contact lenses and also conducts contact lens manufacturing, development and distribution operations in Singapore and the United Kingdom. The Company's U.S. Retail operations sell almost all of the popular brands of contact lenses, including those manufactured by Johnson & Johnson Vision Care, CIBA Vision, Bausch & Lomb and CooperVision.

Recent Transactions and Agreements

International Operations (ClearLab). On February 24, 2004, the Company acquired VisionTec, a developer and manufacturer of daily contact lenses based in the United Kingdom. VisionTec developed a method for low cost, high quality production of daily disposable contact lenses using a unique proprietary material. VisionTec has subsequently been renamed ClearLab UK Ltd (ClearLab UK). The business operates as a research and development and a manufacturing affiliate of ClearLab International. The Company began shipping its daily disposable contact lenses in the first quarter of fiscal 2004 and is currently expanding its production capabilities for these lenses.

ClearLab, the Company's international contact lens development, manufacturing and distribution business, includes the operations of ClearLab International and ClearLab UK. ClearLab recently began to sell frequent replacement lenses in the U.S. through the Company's retail optical partnership. ClearLab will increase its product offerings to the international markets throughout the remainder of fiscal 2005 from its production facilities in Singapore and the U.K. as demand for its product continues to grow.

Japanese License and Royalty Agreement. On December 15, 2004, the Company signed an agreement which grants Menicon Co., Ltd. (Menicon), Japan's largest independent contact lens manufacturer, exclusive rights to develop, manufacture and market certain disposable contact lenses and related intellectual property in Japan.

Under the terms of the agreement, Menicon licenses from the Company different types of intellectual property, including contact lens material, manufacturing technology and related knowledge. In consideration, Menicon is expected to pay nonrefundable license fees of \$18 million, of which \$5 million was paid in December 2004 upon signing the agreement. The remaining \$13 million is expected to be paid over the next three to five years as the Company fulfills its obligations and as corresponding milestones relating to Japanese regulatory approval and Menicon's launch of the product in the Japanese market are met. Of the total \$18 million license fee, \$10 million is guaranteed. Accordingly, the Company is recognizing the guaranteed portion of the license fees from this agreement on a straight-line basis, limited by the amount of cash received, over the period of the Company's continued involvement in meeting its obligations, estimated to be through June of 2007. In the event the Company achieves a milestone (not relating to the guaranteed portion of the license fees) prior to the completion of its obligations under the agreement, the milestone payment will be recognized on a straight-line basis over the remaining period of the Company's continued involvement in meeting its obligations. Upon completion of this agreement, the Company will recognize the remaining milestone payments as the agreed upon milestones are achieved.

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

If Menicon has not received regulatory approval on or before December 31, 2009, it may return all intellectual property covered by the agreement and in-process regulatory approvals to the Company, and the Company may pursue the Japanese market on its own and terminate the exclusive agreement.

Under the terms of the agreement, Menicon will also pay royalties for a period of at least 15 years from the product launch date in Japan on contact lenses sold that were manufactured using the licensed technology, with a guaranteed minimum of \$5 million per year beginning the earlier of the second year after product launch or 2012. The agreement does not include the sale of any of the Company's current equipment, facilities or capacity and is limited to the Japanese contact lens market.

Optical Retail Store Agreement. During the latter part of 2004, the Company entered into an agreement with a regional optical retail chain in Utah in which the two companies would jointly market and sell contact lenses in Utah. In December 2004, the companies began jointly serving these Utah customers. The agreement is for one year, with one year renewals at the option of both parties.

Under the agreement, the Company fulfills substantially all orders taken at the retail optical chain for contact lenses and both parties share in the operating results of the combined contact lens business based on a certain allocation percentage. However, the Company has guaranteed that the retail chain will receive at least \$0.5 million of annual earnings under the arrangement. Additionally, the Company committed to purchase approximately \$0.3 million per year in inventory from the retail chain's source of supply.

The Company does not plan to launch a national network until a resolution can be found to industry practices relating to doctor only lenses. These practices prevent the Company from obtaining certain lenses because some manufacturers refuse to sell these lenses to parties other than eye care practitioners.

Supplier Agreements. The Company has agreements with its top three vendors for improved pricing and marketing support. This support comes in the form of cooperative marketing and rebate programs designed to promote the manufacturer's products and build sales. As part of its ongoing relationship with its suppliers, the Company periodically reviews its specific marketing plans and negotiates cooperative marketing programs and product pricing.

Regulatory Considerations

Fairness to Contact Lens Consumer Act. In November 2003, Congress passed the Fairness to Contact Lens Consumer Act (FCLCA), which establishes a national uniform standard for both eye care practitioners and direct marketers with regard to releasing and verifying consumer contact lens prescriptions as well as other requirements relating to the sale of contact lenses. The FCLCA became effective February 4, 2004, and now requires all eye care practitioners to give patients a copy of their prescription as soon as they have been fitted for contact lenses, whether the patients ask for it or not. It also directs contact lens sellers to contact eye care practitioners to request verification of consumer prescriptions before shipping all orders (if the prescription is not already on file), and it provides that failure to respond within eight business hours shall result in the prescription being presumed valid, thereby eliminating the ability of eye care practitioners to impede sales by direct marketers simply by ignoring or refusing to respond to their requests to verify prescriptions. The FCLCA also provides that prescriptions will be valid for a minimum of at least one year (absent some special medical reason justifying a shorter period). It also directed the Federal Trade Commission (FTC) to conduct a study examining the strength of competition in the market for contact lenses and to submit a report to Congress within twelve months of the FCLCA effective date. This FTC completed and published this study on February 15, 2005, with no recommendations for further changes in federal law.

Satisfying the prescription verification requirement of the FCLCA obligates a contact lens seller either to obtain a copy of the prescription itself or to verify the prescription by direct communication with the customer's prescriber. Consistent with this requirement, the Company's current operating practice is to require all customers to provide either a valid copy of their prescription or the contact information for their prescriber so that the Company can verify their prescription by direct communication with their prescriber. If the Company does not have a valid copy of the customer's prescription, the Company directly communicates to the customer's prescriber the precise prescription information received from the customer and informs the prescriber that it will proceed with the sale based on this prescription information unless the prescriber advises it within eight business hours that such prescription information is expired or otherwise invalid. If the prescriber properly advises the Company within this time period that the customer's prescription is expired or otherwise invalid, the Company's practice is to cancel the customer's order. On the other hand, if the prescriber either advises the Company that the prescription is valid or fails to respond properly within the required time period, the Company's practice is to complete the sale based on the prescription information communicated to the prescriber, as expressly permitted by the FCLCA. The Company retains copies of the written prescriptions that it receives and maintains records of its communications with the customer's prescriber. The FCLCA provides for several means of direct communication with eye care practitioners,

and the Company may alter its prescription verification procedures from time to time in keeping with the FCLCA and FTC guidelines.

On October 13, 2005, the Company received a letter from the Federal Trade Commission (FTC) notifying the Company that the FTC had received numerous complaints from eye care providers about the Company s inbound fax system. Copies of the FTC letter and the Company s response to the FTC are available on the Company s website at www.order.1800contacts.com/compliance. The FTC letter states that the complaints allege that [the Company s] fax lines are often busy, and that prescribers are therefore unavailable to communicate with it regarding verification requests.

In response to this letter from the FTC, the Company conducted a thorough review of its systems and found that its verification fax system (provided by a third party with capacity to receive more than a hundred simultaneous faxes) has maintained 99.96% availability to date in 2005. However, the Company points out in its response to the FTC that with millions of orders processed each year by the Company, even this near perfect uptime could result in instances where a small number of prescribers find the system unavailable for a brief period of time. In order to ensure compliance with the FCLCA, the Company suspends shipping during a verification system outage and does not take advantage of any system outages to reduce the eight business hours available to prescribers to respond to verification requests as required by the FCLCA.

Results of Operations

The Company's fiscal year consists of a 52/53-week period ending on the Saturday nearest to December 31. Fiscal 2005 is a 52-week year and will end on December 31, 2005.

The Company has two operating segments referred to below. The Company's domestic segment is represented by operations within the U.S. and is referred to as U.S. Retail by the Company, whereas the Company's international segment is represented by operations in both Singapore and the U.K. and is referred to as ClearLab by the Company.

The following table presents the Company's results of operations expressed as a percentage of net sales for the periods indicated:

	Quarter Ended		Three Quarters Ended	
	October 2, 2004	October 1, 2005	October 2, 2004	October 1, 2005
NET SALES	100.0%	100.0%	100.0%	100.0%
COST OF GOODS SOLD	61.3	62.0	61.6	62.0
Gross profit	38.7	38.0	38.4	38.0
SELLING, GENERAL & ADMINISTRATIVE EXPENSES:				
Advertising	11.4	10.9	14.3	11.1
Legal and professional	1.8	2.0	2.7	1.9
Research and development	1.0	0.7	1.2	1.3
Purchased in-process research and development			0.1	
Other selling, general & administrative	19.0	22.2	19.9	20.4
Total selling, general & administrative expenses	33.2	35.8	38.2	34.7
INCOME FROM OPERATIONS	5.5	2.2	0.2	3.3
OTHER EXPENSE, net	(0.4)	(1.2)	(0.8)	(1.4)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	5.1	1.0	(0.6)	1.9
PROVISION FOR INCOME TAXES	(2.7)	(2.0)	(0.7)	(2.1)
NET INCOME (LOSS)	2.4%	(1.0)%	(1.3)%	(0.2)%

Net sales. Net sales for the quarter ended October 1, 2005 increased 7.0% to \$60.9 million from \$56.9 million for the quarter ended October 2, 2004. For the three quarters ended October 1, 2005, net sales increased 15.7% to \$182.5 million from \$157.7 million for the three quarters ended October 2, 2004. Net sales for the Company's U.S. Retail operations, for the third quarter of fiscal 2005 and the first three quarters of fiscal 2005 were \$55.8 million and \$168.9 million, respectively, an increase from the prior year periods of 2% and 10%, respectively. Approximately half of the year-to-date increases in U.S. Retail net sales are due to a decrease in the number and percentage of orders the Company canceled as a result of prescription verification procedures (see Regulatory Considerations). For the third quarter of fiscal 2005 a decrease in the number and percentage of orders the Company canceled accounted for approximately \$0.5 million of the increase in net sales from the prior year quarter. The Company believes the cancellation rate has now stabilized and does not anticipate any significant change in the balance of fiscal 2005. The Company is continually taking steps to minimize canceled orders, including continued development of a more integrated national retail store network and the continued development of internal procedures to help obtain the

necessary prescription information that is required to fulfill an order. The balance of the increase in U.S. Retail net sales for the third quarter and first three quarters of fiscal 2005 can be attributed largely to an increase in average order size due principally to an increased number of customer rebate programs instituted during fiscal 2004 and the first three quarters of fiscal 2005 and an increase in accessory sales.

U.S. Retail net sales for the first three quarters of fiscal 2005 were negatively impacted by the Company's decision during the fourth quarter of fiscal 2004 to suspend sales of a specific brand of lens, as the Company is unable to obtain sufficient quantities of this lens from anyone other than the manufacturer, who refuses to sell the Company this lens. Sales of this lens represented approximately 2.5% of the Company's fiscal 2004 U.S. Retail net sales. Additionally, net sales during the third quarter of fiscal 2005 were negatively impacted by approximately \$0.7 million due to temporary disruptions in service to the Company's internet customers as the Company upgraded its website to a newer version with enhanced features.

Net sales for ClearLab for the third quarter of fiscal 2005 and the first three quarters of fiscal 2005 were \$6.0 million and \$14.9 million, respectively. Net sales for ClearLab, for the third quarter of fiscal 2004 and the first three quarters of fiscal 2004 were \$1.9 million and \$4.5 million, respectively. ClearLab's results for the first three quarters of fiscal 2005 include \$1.0 million per quarter in license fees from the Company's Japanese license agreement. Additionally, \$0.9 million and \$1.3 million of ClearLab's sales during the third fiscal quarter and first three fiscal quarters of 2005, respectively, were intercompany sales to the Company's U.S. retail business and are eliminated for consolidation purposes, as the Company recognizes retail sales when the product is sold to external customers. During the first three quarters of fiscal 2005, ClearLab realized increased sales to existing and new customers as it has enhanced its product offerings and expanded its production capabilities.

Gross profit. Consolidated gross profit as a percentage of net sales for the quarter and three quarters ended October 1, 2005 was 38.0% for each period compared to 38.7% and 38.4%, respectively, for the quarter and three quarters ended October 2, 2004.

Gross profit as a percentage of net sales for the Company's U.S. Retail operations decreased to 39.3% for the third quarter of fiscal 2005 from 40.5% in the third quarter of fiscal 2004. This decrease can be attributed largely to an increased number of customer rebate programs instituted during fiscal 2004 and the first three quarters of fiscal 2005. However, gross profit as a percentage of net sales for the Company's U.S. Retail operations remained relatively consistent at 39.6% from 39.8% for the three quarters ended October 1, 2005 and October 2, 2004, respectively.

Gross profit as a percentage of net sales for ClearLab was 30.8% and 21.2% for the quarter and three quarters ended October 1, 2005, respectively. For the prior year quarter and three quarters ended October 2, 2004, gross profit as a percentage of net sales was negative due to the start-up nature of ClearLab UK, which was acquired on February 24, 2004. The increase in gross profit as a percentage of net sales during the fiscal 2005 periods is due mainly to the Company's continued improvement of its sales volume and manufacturing efficiencies. The Company expects to see continued improvement in gross margins from ClearLab throughout fiscal 2005.

Advertising expense. Advertising expense for the quarter ended October 1, 2005 was \$6.6 million, an increase of \$0.1 million from the quarter ended October 2, 2004. As a percentage of net sales, advertising expense decreased to 10.9% for the third quarter of fiscal 2005 from 11.4% for the third quarter of fiscal 2004. For the three quarters ended October 1, 2005, advertising expense was \$20.3 million, a decrease of \$2.3 million from the three quarters ended October 2, 2004. As a percentage of net sales, advertising expense decreased to 11.1% for the first three quarters of fiscal 2005 from 14.3% for the first three quarters of fiscal 2004. The Company expects advertising expenses of approximately \$25 million for fiscal 2005. However, if opportunities present themselves, the Company may increase advertising spending above currently planned levels. The Company's experience has been that increases in advertising expenditures have a direct impact on the growth of net sales not only in the current period but also in future periods.

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

The Company expenses all advertising costs when the advertising first takes place. As a result, quarter-to-quarter comparisons are impacted within and between quarters by the timing of television, radio and Internet advertisements and by the mailing of the Company's printed advertisements. The volume of mailings and other advertising may vary in different quarters and from year to year depending on the Company's assessment of prevailing market opportunities.

Legal and professional fees. Legal and professional fees for the quarter ended October 1, 2005 increased

\$0.2 million to \$1.2 million from the quarter ended October 2, 2004. As a percentage of net sales, legal and professional fees increased to 2.0% for the third quarter of fiscal 2005 from 1.8% for the third quarter of fiscal 2004. For the three quarters ended October 1, 2005, legal and professional fees decreased \$0.8 million to \$3.4 million from the three quarters ended October 2, 2004. As a percentage of net sales, legal and professional fees decreased to 1.9% for the first three quarters of fiscal 2005 from 2.7% for the first three quarters of fiscal 2004.

During the first quarter of fiscal 2004 the Company invested considerable effort preparing comments for the Federal Trade Commission (FTC) relating to final rules associated with the FCLCA. During the first three quarters of fiscal 2005, the Company continued to incur professional fees for Sarbanes-Oxley compliance, and other internal control initiatives, as well as ongoing legal, lobbying and regulatory initiatives.

The Company will continue to focus its efforts on compliance with federal rules and regulations as well as continue to support legal and legislative initiatives that it believes will benefit contact lens wearers and the industry.

Research and development expenses. Research and development expenses for the quarter ended October 1, 2005 decreased to \$0.4 million, or 0.7% of net sales, from \$0.6 million, or 1.0% of net sales, from the quarter ended October 2, 2004. For the three quarters ended October 1, 2005, research and development expenses were \$2.3 million, or 1.3% of net sales, up from \$1.9 million, or 1.2% of net sales, for the three quarters ended October 2, 2004. During the first three quarters of fiscal 2005, the Company continued to fund research and development efforts for ClearLab's operations.

Total fiscal 2005 research and development costs will be dependent on progress with research and development efforts relating to expanding ClearLab's product offering and developing its intellectual property.

Other selling, general and administrative expenses. Other selling, general and administrative expenses for the quarter ended October 1, 2005 increased approximately \$2.7 million from the quarter ended October 2, 2004. As a percentage of net sales, other selling, general and administrative expenses for the quarter ended October 1, 2005 also increased to 22.2% from 19.0% for the quarter ended October 1, 2004. As a percentage of net sales, other selling, general and administrative expenses for the three quarters ended October 1, 2005 increased to 20.4% from 19.9% for the three quarters ended October 2, 2004; such expenses also increased by approximately \$5.9 million for the same period.

The Company's U.S. Retail other selling, general and administrative expenses increased by approximately \$1.3 million for the quarter ended October 1, 2005 from the quarter ended October 2, 2004; additionally, such expenses also increased as a percentage of net sales to 19.7% from 17.6% respectively, for the same period. ClearLab's other selling, general and administrative expenses increased by approximately \$1.5 million for the quarter ended October 1, 2005 from the quarter ended October 2, 2004. For the three quarters ended October 1, 2005, the Company's U.S. Retail other selling, general and administrative expenses increased by approximately \$3.6 million from the three quarters ended October 2, 2004. As a percentage of net sales, U.S. Retail other selling, general and administrative expenses for the three quarters ended October 1, 2005 increased to 18.9% from 18.5% for the three quarters ended October 2, 2004. ClearLab's other selling, general and administrative expenses increased by approximately \$2.3 million for the three quarters ended October 1, 2005 from the three quarters ended October 2, 2004.

The majority of the increase for U.S. Retail relates to the continued enhancement of its operating infrastructure and management team to meet the demands of the business and variable costs associated with higher net sales and the requirements of the FCLCA. A majority of ClearLab's

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

increase related to the enhancement and scale up of its operating infrastructure, including the operations of ClearLab UK, which was partially offset in the third quarter by a Singapore government grant of approximately \$0.4 million for certain qualifying expenditures which was recorded as a reduction of selling, general and administrative expenses.

The Company expects other selling, general and administrative expenses to fluctuate as a percentage of net sales as the Company continues to grow and expand its U.S. and international operations.

Other expense, net. Other expense increased to approximately \$0.8 million and \$2.6 million for the quarter and three quarters ended October 1, 2005, respectively, from approximately \$0.2 million and \$1.3 million for the

quarter and three quarters ended October 2, 2004, respectively. For the third quarter of fiscal 2005, other expense consisted mainly of approximately \$0.3 million in interest expense and \$0.3 million in foreign currency exchange transaction losses. Other expense in the third quarter of fiscal 2004 consisted mainly of interest expense of \$0.4 million, offset by unrealized foreign exchange transaction gains of approximately \$0.1 million. For the first three quarters of fiscal 2005, other expense consisted mainly of foreign currency exchange transaction losses of approximately \$1.4 million and interest expense of approximately \$1.0 million. For the first three quarters of fiscal 2004, other expense consisted mainly of interest expense of approximately \$1.2 million and foreign currency exchange transaction losses of less than \$0.1 million. The foreign currency exchange transaction losses related primarily to intercompany loans to ClearLab.

Income taxes. The Company is taxed in three separate jurisdictions - U.S., Singapore and the United Kingdom. The Company's effective U.S. income tax rate for the three quarters ended October 1, 2005 is approximately 40% as compared with the 39% reported for the three quarters ended October 2, 2004. During the first three quarters of fiscal 2005, the Company did not record a tax benefit for the loss from the operations of ClearLab International due to the uncertainty with respect to the realization of a tax benefit in Singapore. For the first three quarters of fiscal 2005, the Company provided a valuation allowance for the full amount of deferred income tax assets in Singapore. For the first three quarters of fiscal 2005, the Company recorded a tax benefit for the loss from operations of ClearLab UK using an effective tax rate of approximately 25%. The Company provided a valuation allowance for a portion of the deferred income tax assets in the United Kingdom based on the excess of the deferred tax liabilities recorded as of the date of acquisition of ClearLab UK over the deferred tax assets generated by the loss from operations during fiscal 2004 and the expected loss for fiscal 2005, which operating loss can be carried forward indefinitely. The Company's effective income tax rates may change as facts and circumstances change. The Company anticipates that its fiscal 2005 effective income tax rate for the U.S. and the United Kingdom will be consistent with the respective effective rates recorded during the first three quarters of fiscal 2005.

Liquidity and Capital Resources

The Company's principal sources of liquidity have been cash provided by operating activities and proceeds from debt financings. The Company's principal uses of cash have been to meet debt service requirements, finance acquisitions, finance capital expenditures, fund working capital needs and repurchase common stock. The Company anticipates that these uses will continue to be the principal demands on its cash in the future. As of October 1, 2005, the Company had net working capital of approximately \$7.2 million, compared to \$10.0 million as of January 1, 2005.

The Company believes that its cash on hand, together with cash generated from operating activities and the borrowings available through the credit facility, will be sufficient to support planned operations through the foreseeable future. Should the Company's plans or expectations change, the Company may be required to seek additional sources of funds and there can be no assurance that such funds will be available on satisfactory terms. Failure to obtain such financing could delay or prevent the Company's planned growth, which could adversely affect the Company's business, financial condition, liquidity and results of operations.

As a result of regulatory requirements, the Company's liquidity, capital resources and results of operations may be negatively impacted in the future if the Company incurs increased costs (including legal fees) or fines, is prohibited from selling its products or experiences losses of a substantial portion of the Company's customers for whom the Company is unable to obtain or verify a prescription due to the requirements of the FCLCA.

The Company has a loan agreement with a U.S. bank providing for a revolving credit facility for borrowings of up to \$25.6 million as of October 1, 2005, which amount is reduced thereafter on the first day of each September, December, March and June by \$0.4 million until the maturity date of February 27, 2007. Additionally, the agreement provides for letters of credit up to a maximum of \$15 million outstanding or payable at any time. The loan agreement specifies that if the maximum leverage ratio, as defined in the agreement, is greater than 2.5, then the amounts outstanding on the revolving credit facility together with the amount of all outstanding letters of credit can at no time exceed the Company's book value of inventory. As of October 1, 2005, the Company was not subject to this restriction and could borrow up to \$25.6 million. Outstanding borrowings on the revolving credit facility bear interest at a floating rate equal to the lender's prime interest rate plus a margin or the lender's LIBOR rate plus a margin. The interest rate is adjusted quarterly and ranges between prime plus 0.0 percent and prime plus 1.25 percent or between the applicable LIBOR rate plus 2.0 percent and the applicable LIBOR rate plus 3.25 percent, depending on the Company's maximum leverage ratio. As of October 1, 2005, the prime rate margin is 0.0 percent and the LIBOR rate margin is 2.0 percent. Interest is payable monthly. As of October 1, 2005, the Company's outstanding borrowings on the credit facility, including bank overdrafts, were \$19.4 million. Of this amount, \$10.0 million bore interest at the lender's LIBOR rate plus 2.0 percent (5.83% at October 1, 2005) and the remaining \$9.4 million bore interest at the lender's prime rate plus 0.0 percent (6.75% at October 1, 2005). The facility requires the quarterly payment of an unused credit fee which ranges from 0.38 percent to 0.5 percent, depending on the Company's maximum leverage ratio.

All outstanding balances on this credit facility are secured by substantially all of the Company's U.S. assets, subsidiary debt instruments, 100 percent ownership interests in all domestic subsidiaries and 65 percent ownership interests in foreign subsidiaries directly owned by the Company. The loan agreement includes various financial covenants including a capital expenditure limit, a maximum leverage ratio, a minimum working capital requirement, a minimum fixed charge coverage ratio and a minimum net worth requirement. The loan agreement does not permit the Company or its subsidiaries to dissolve, sell, dispose or merge all of their assets or acquire all of the assets of any entity without the written consent of the U.S. bank, unless the transaction meets the definition of a Permitted Acquisition Basket, as defined in the agreement. The loan agreement also places a limit on the amount the Company can loan to any entity, outside the normal course of business. Additionally, the agreement does not permit the Company to declare or pay any cash dividends, to repurchase its stock or to perform other similar equity transactions prior to December 31, 2005; thereafter, such transactions are subject to other terms. This agreement defines several customary events of default including any material adverse change or any event that occurs which may cause a material adverse change in the Company's or its subsidiaries' condition.

Cross default clauses exist such that if the Company were in default on its U.S. debt, the Company would also be in default on its Singapore debt. If the Company were in default on its Singapore bank term loan, the Company would also be in default on its note payable to the former parent of ClearLab International and its restated loan agreement with its U.S. bank.

Cash flows from operating activities. For the three quarters ended October 1, 2005 and October 2, 2004, net cash provided by operating activities was approximately \$5.2 million and \$5.0 million, respectively. In the fiscal 2005 period, cash was provided primarily by adjustments to the net loss for non-cash items, increases in accounts payable and accrued liabilities as well as a decrease in other receivables partially offset by increases in inventories, accounts receivable, other current assets as well as from decreases in income taxes payable and unearned revenue. In the fiscal 2004 period, cash was provided primarily by a decrease in inventories offset by increases in accounts receivable and other current assets. Also in the 2004 period, cash was provided by an increase in various accrued liabilities partially offset by a decrease in accounts payable.

Cash flows from investing activities. The Company used approximately \$12.3 million and \$14.1 million for investing activities in the three quarters ended October 1, 2005 and October 2, 2004, respectively. In the first three quarters of fiscal 2005, the Company's deposits increased by approximately \$2.1 million of which the majority relates to manufacturing equipment at ClearLab. The Company also purchased approximately \$0.6 million of intangible assets during the fiscal 2005 period. In the fiscal 2004 period, the Company paid approximately \$3.8 million in cash (including \$0.6 million in transaction costs) in connection with the acquisition of VisionTec. The Company also

purchased approximately \$4.0 million of intangible assets during the fiscal 2004 period.

Capital expenditures for infrastructure improvements for the first three quarters ended October 1, 2005 and October 2, 2004 were approximately \$9.5 million and \$6.0 million, respectively. Of these amounts, approximately \$5.9 million and \$3.5 million relate to ClearLab purchases for the 2005 and 2004 fiscal periods, respectively. The Company anticipates additional capital expenditures in fiscal 2005 for infrastructure as it continues to expand and improve operating facilities, telecommunications systems and management information systems in order to handle future operations of both its U.S. and international operations.

Financing activities. During the three quarters ended October 1, 2005 and October 2, 2004, net cash provided by financing activities was approximately \$4.1 million and \$8.5 million, respectively. In the first three fiscal quarters of 2005, the Company had net borrowings on its credit facility of approximately \$5.0 million and made principal payments on debt obligations and capital lease obligations of approximately \$1.3 million. In the first three fiscal quarters of 2004, the Company had net borrowings on its credit facility of approximately \$16.4 million and made principal payments on debt obligations and capital lease obligations of approximately \$8.7 million and incurred approximately \$0.2 million in debt issuance costs. The Company also received a governmental regional development grant in the U.K. of approximately \$0.9 million. This grant was designed to assist in employment creation while the amount of the grant is based on ClearLab UK capital expenditures. In the fiscal 2005 and 2004 periods, proceeds from the exercise of common stock options were \$0.4 million and \$0.2 million, respectively.

As of October 1, 2005, the Company had an unsecured, non-interest bearing note to ClearLab International's chief technology officer with a principal balance of SGD\$1,375,000 (USD\$814,000). The note payable is discounted at 7%. Payments are due in equal monthly installments through July 2007.

As of October 1, 2005, the Company had a term loan payable to a Singapore bank with a principal balance of SGD\$6,110,000 (USD\$3,618,000) that bears interest at 6.75% and is secured by substantially all of the assets of ClearLab International. Interest payments are due monthly. Principal payments are due in monthly installments through December 2007. This note also contains various financial covenants including minimums on net worth and shareholders' funds. The Company has guaranteed this term loan.

As of October 1, 2005, the Company also had a note payable to the former parent of ClearLab International with a principal balance of SGD\$6,892,000 (USD\$4,082,000) that bears interest at 6% and has a subordinated position to the term loan payable to the Singapore bank. The note payable is discounted at 7%. Interest payments are due monthly. Principal payments are due in monthly installments from January 2008 through December 2009. The Company has guaranteed this note.

The Company leases various manufacturing and other equipment from financing companies under capital lease arrangements. All of the equipment is maintained at the Singapore and United Kingdom facilities. The majority of the leases were assumed in connection with the Company's acquisitions of ClearLab International and ClearLab UK. As of October 1, 2005, the present value of future minimum lease payments was approximately \$0.1 million with payments scheduled through fiscal 2009.

Contractual Obligations and Commitments

Edgar Filing: 1 800 CONTACTS INC - Form 10-Q

Subsequent to January 1, 2005, there have been no material changes to the Company's contractual obligations and commitments, outside the normal course of business.

New Accounting Pronouncements

In December 2004, the FASB issued SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R), which replaces SFAS No. 123, Accounting for Stock-Based Compensation, (SFAS 123) and supercedes APB Opinion No. 25, Accounting for Stock Issued to Employees. SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values beginning with the first annual period after June 15, 2005, with early adoption encouraged. The pro forma disclosures previously permitted under SFAS 123 will no longer be an alternative to financial statement recognition. The Company is required to adopt SFAS 123R in the first fiscal quarter of 2006, beginning January 1, 2006. Under SFAS 123R, the Company must determine the appropriate fair value model to be used for valuing share-based

payments, the amortization method for compensation cost and the transition method to be used at date of adoption. The transition methods include prospective and retroactive adoption options. Under the retroactive option, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The prospective method requires that compensation expense be recorded for all unvested stock options at the beginning of the first quarter of adoption of SFAS 123R, while the retroactive methods would record compensation expense for all unvested stock options and beginning with the first period restated. The Company is evaluating the requirements of SFAS 123R and expects that the adoption of SFAS 123R will have a material adverse impact on its consolidated results of operations and earnings per share. The Company has not yet determined the method of adoption or the effect of adopting SFAS 123R.

In November 2004, the FASB issued SFAS No. 151, *Inventory Costs* (SFAS 151). The provisions of this statement become effective for the Company in fiscal 2006. SFAS 151 amends the existing guidance on the recognition of inventory costs to clarify the accounting for abnormal amounts of idle expense, freight, handling costs, and wasted material (spoilage). Existing rules indicate that under some circumstances, items such as idle facility expense, excessive spoilage, double freight, and rehandling costs may be so abnormal as to require treatment as current period charges. SFAS 151 requires that those items be recognized as current period charges regardless of whether they meet the criterion of so abnormal . In addition, SFAS 151 requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. The Company is required to adopt SFAS 151 in the fiscal year beginning January 1, 2006. The Company has not yet determined the impact of SFAS 151.

In June 2005, the FASB issued SFAS No. 154, *Accounting Changes and Error Corrections* (SFAS 154) a replacement of APB Opinion No. 20, *Accounting Changes*, and SFAS No. 3, *Reporting Accounting Changes in Interim Financial Statements*. Under the provisions of SFAS No. 154, voluntary changes in accounting principles are applied retrospectively to prior periods financial statements unless it would be impractical. SFAS No. 154 supersedes APB Opinion No. 20, which required that most voluntary changes in accounting principles be recognized by including in the current period s net income the cumulative effect of the change. SFAS No. 154 also makes a distinction between retrospective application of a change in accounting principle and the restatement of financial statements to reflect the correction of an error. The provisions of SFAS No. 154 are effective for accounting changes made in fiscal years beginning after December 15, 2005. The Company does not expect adoption to have a material impact on the consolidated financial statements, results of operations or liquidity of the Company.

Critical Accounting Policies

Accounting polices that require significant judgments and estimates include revenue recognition (including sales returns and allowances and customer rebates); realizability of inventories; realizability of deferred income tax assets; accounting for business combinations including assessment of realizability of long-lived assets; stock-based compensation; and legal and regulatory contingencies. A description of the Company s significant accounting policies is included in the notes to the consolidated financial statements included in the Company s Form 10-K for the fiscal year ended January 1, 2005. Judgments and estimates are based on historical experience as well as relevant facts and circumstances known at each reporting date. Actual results may differ from these estimates.

Sales are generally recognized when products are shipped and the customer takes ownership and assumes risk of loss, collection of the related receivable is reasonably assured, persuasive evidence of an arrangement exists and the sales price is fixed or determinable. U.S. Retail net sales consist of product sales less a provision for sales returns and allowances and estimated customer rebates. The Company accrues an estimated amount for unclaimed customer rebates and sales returns and allowances based on historical information, adjusted for economic trends. To the extent actual rebates, returns and allowances vary from historical experience revisions to the allowances may be required. ClearLab net sales consist of product sales less a provision for sales returns and allowances. The Company provides its customers with standard industry payment terms and performs ongoing credit evaluations of its customers and provides for doubtful accounts to the extent determined necessary based on historical data and current economic trends. ClearLab net sales also include license fees from the Company s Japanese license agreement. Cash payments received from this license are recognized systematically over the periods that the fees are earned by the Company.

In assessing the realizability of inventories, the Company makes judgments as to future demand requirements and product expiration dates. The inventory requirements change based on projected customer demand, which changes due to fluctuations in market conditions and product life cycles.

The Company has significant long-lived tangible and intangible assets consisting of property, plant and equipment, goodwill and definite-lived intangibles. These assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. In addition, the Company performs an impairment test related to goodwill at least annually. An impairment analysis related to long-lived tangible and definite-lived intangible assets requires the assessment of expected future undiscounted cash flows over the remaining useful life of the asset. An impairment analysis of goodwill requires the use of a fair-value based analysis. All of the goodwill and a significant portion of the other long-lived assets were generated from the Company's acquisitions of ClearLab International, ClearLab UK and Lens1st/Lens Express. If forecasts and assumptions used to support the realizability of long-lived assets change in the future, significant impairment charges could result that would adversely affect the Company's results of operations and financial position.

Deferred income tax assets are assessed for recoverability and valuation allowances are provided as necessary to reduce deferred income tax assets to amounts expected to be realized. Should expectations of taxable income change in future periods, it may become necessary to change the valuation allowance, which could affect the Company's results of operations in the period such determination is made. The Company records an income tax provision or benefit at a rate that is based on expected results for the fiscal year. If future changes in market conditions cause actual results to be more or less favorable, adjustments to the effective income tax rate on a quarterly basis could be required.

The Company records liabilities for legal and regulatory matters when the contingency is both probable and reasonably estimable. The Company is involved in several legal and regulatory matters. The Company, after consultation with legal counsel, believes that the ultimate dispositions of these matters will not have a material impact on its financial position, liquidity or results of operations. However, there can be no assurance that the Company will be successful in its efforts to satisfactorily resolve these matters and the ultimate outcome could result in a material negative impact on the Company's financial position, liquidity or results of operations.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this Form 10-Q are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements involve risks and uncertainties and often depend on assumptions, data or methods that may be incorrect or imprecise. The Company's future operating results may differ materially from the results discussed in, or implied by, forward-looking statements made by the Company. Factors that may cause such differences include, but are not limited to, those discussed below and the other risks detailed in the Company's other reports filed with the Securities and Exchange Commission. Words such as *believes*, *anticipates*, *expects*, *future*, *intends*, *would*, *may* and similar expressions are intended to identify forward-looking statements. The Company undertakes no obligation to revise any of these forward-looking statements to reflect events or circumstances after the date hereof.

Factors that may affect future results may include, but are not limited to the following:

The Company may encounter unforeseen difficulties in managing its future growth;

The Company obtains a large percentage of its retail inventory from a limited number of suppliers, with a single manufacturer accounting for 35%, 23% and 44% of the Company's inventory purchases in fiscal 2002, 2003 and 2004, respectively. In addition, the Company's top three suppliers accounted for 63%, 59% and 83% of the Company's inventory purchased in fiscal 2002, 2003 and 2004, respectively;

Continued growth of doctors only lenses could compel contact lens manufacturers to adopt or expand a doctors only distribution strategy for all or some of the lenses they manufacture.

The Company may continue to experience order cancellations due to the prescription verification requirements of the Fairness to Contact Lens Consumers Act;

The Company may not be able to establish a sufficient network of eye care practitioners to prescribe the products manufactured by the Company;

The Company may incur unforeseen costs or not realize all of the anticipated benefits from its relationships with Johnson & Johnson Vision Care, CIBA Vision and Menicon;

Because the Company does not manufacture most of the contact lenses that it sells, the Company cannot ensure that all of the contact lenses it sells meet all federal regulatory requirements;

It is possible that the FDA could consider certain of the contact lenses the Company sells to be misbranded or adulterated;

The Company, through a wholly owned subsidiary, is registered as an initial distributor/importer with the FDA, and the Company's failure to comply with certain regulatory responsibilities and requirements could result in enforcement by the FDA;

The Company currently purchases a portion of its products from unauthorized distributors and is not an authorized distributor for some of the products that it sells;

The Company may continue to incur significant legal and professional fees related to its legal matters and its efforts to proactively influence the industry on behalf of itself and consumers;

The Company's quarterly results are likely to vary based upon the level of sales and marketing activity in any particular quarter;

The Company is dependent on its telephone, Internet and management information systems for the sale and distribution of contact lenses;

The retail sale of contact lenses is highly competitive and certain of the Company's competitors are large, national optical chains that have greater resources than the Company;

The demand for contact lenses could be substantially reduced if alternative technologies to permanently correct vision gain in popularity;

Increases in the cost of shipping, postage or credit card processing could harm the Company's business;

The Company's business could be harmed if it is required to collect state sales tax on the sale of all products;

The Company faces an inherent risk of exposure to product liability claims in the event that the use of the products it manufactures or sells results in personal injury;

The Company conducts its retail operations through a single distribution facility;

The Company's success is dependent, in part, on continued use of the Internet;

Government regulation and legal uncertainties relating to the Internet and online commerce could negatively impact the Company's business operations;

Changing technology could adversely affect the operation of the Company's website;

The Company may not be able to develop and manufacture viable, high quality contact lenses for sale to consumers that meets all federal regulatory requirements;

The Company may not be able to fully integrate the operations of its acquisitions into its business;

Consumer acceptance of the Company's manufactured products may not meet the Company's expectations;

The Company's intellectual property rights may be challenged;

The Company may encounter legal, regulatory and government agency oversight risks with foreign operations;

The Company may not be able to adequately manage its foreign currency risk;

The Company may be required to reduce the carrying value of its intangible assets if events and circumstances indicate the remaining balance of intangible assets may not be recoverable;

The Company may not be able to complete its milestones and obligations in a timely manner under the Japanese license agreement;

The Company may not receive the amount of license fees and royalties that it presently anticipates under the Japanese license agreement;

A portion of the Company's sales may be found not to comply with state laws and regulations concerning the delivery and sale of contact lenses; and

The Company does not have any property rights in the 1-800 CONTACTS telephone number or the Internet addresses that it uses.

Item 3. *Quantitative and Qualitative Disclosures About Market Risk*

Interest Rate Risk. As of October 1, 2005, the Company was exposed to changes in interest rates relating to its revolving credit facility and other debt obligations. The revolving credit facility bears interest at a variable rate based on the U.S. prime rate or LIBOR. The Company's outstanding borrowings on the credit facility, including bank overdrafts, were approximately \$19.4 million as of October 1, 2005. The remainder of the Company's interest bearing debt obligations, including capital lease obligations, is denominated in Singapore dollars and British pounds and bears interest at a fixed rate. As of October 1, 2005, the face amounts of the outstanding borrowings on these fixed rate debt obligations were approximately \$7.8 million. If interest rates were to change by a full percentage point, the net impact on interest expense would be approximately \$0.2 million per year.

Foreign Currency Risk. The Company faces foreign currency risks primarily as a result of its acquired Singapore and United Kingdom operations and the intercompany balances between its U.S. and these international operations which are denominated in U.S. dollars. The functional currency of the Company's Singapore operations is the Singapore dollar. The Company has debt and other long-term obligations of approximately \$8.6 million that are denominated in Singapore dollars and mature over the next five years. If the U.S. dollar weakens relative to the Singapore dollar, additional funds may be required to meet these obligations if the debt cannot be adequately serviced from the Singapore operations. Fluctuations in exchange rates between the U.S. dollar and the Singapore dollar could lead to additional currency exchange losses or gains on the intercompany balances and transactions denominated in currencies other than the functional currency. For the first three quarters of fiscal 2005, the Company recorded a foreign currency transaction loss of approximately \$0.6 million on the intercompany balances between the U.S. and Singapore operations. From the date of the ClearLab International acquisition, July 24, 2002, through November 2, 2005 the exchange rate has fluctuated approximately 3.0 percent (weakening of the U.S. dollar). If the Singapore dollar were to weaken against the U.S. dollar by 10 percent, the Company would record a \$2.2 million dollar foreign currency loss on the intercompany balances that exist as of October 1, 2005.

The functional currency of the Company's United Kingdom operations is the British pound. Fluctuations in exchange rates between the U.S. dollar and the British pound could lead to additional currency exchange losses or gains on intercompany balances and transactions denominated in currencies other than the functional currency. For the first three quarters of fiscal 2005, the Company recorded a foreign currency transaction loss of approximately \$0.8 million on the intercompany balances between the U.S. and United Kingdom operations. From the date of the ClearLab UK acquisition, February 24, 2004, through November 2, 2005 the exchange rate has fluctuated approximately 5.4 percent (strengthening of the U.S. dollar). If the British pound were to weaken against the U.S. dollar by 10 percent, the Company would record a \$1.2 million dollar foreign currency loss on the intercompany balances that exist as of October 1, 2005.

The Company has not entered into any foreign currency derivative financial instruments; however, it may choose to do so in the future in an effort to manage or hedge its foreign currency risk.

Item 4. *Controls and Procedures*

(a) Evaluation of disclosure controls and procedures. The Company's Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) as of the end of the period covered by this report (the Evaluation Date), have concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were adequate and effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities.

(b) Changes in internal controls. There were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's disclosure controls and procedures subsequent to the Evaluation Date. As a result, no corrective actions were taken.

The Company's management, including its Chief Executive Officer and Chief Financial Officer, does not expect that the Company's disclosure controls and procedures or its internal controls will prevent all error and all

fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been deducted.

PART II. OTHER INFORMATION

Item 1. *Legal Proceedings*

See notes to condensed consolidated financial statements.

Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds*

None.

Item 3. **Defaults Upon Senior Securities**

None.

Item 4. **Submission of Matters to a Vote of Security Holders**

None.

Item 5. **Other Information**

On August 31, 2005, the Company hired Robert Main as the Company's Senior Vice President, Professional Network. Although a definitive agreement is not yet finalized, the principal terms of Mr. Main's employment are summarized as follows: four year employment term, with a possible one-year severance payment upon termination without cause; annual salary of approximately \$210,000; annual bonus range between 0%-60% of the annual base salary; and a grant of the Company's restricted shares, with the amount, vesting conditions and other terms of such grant to be determined in accordance with, and upon final approval of, a long-term incentive plan. The Company will file a copy of the finalized, definitive employment agreement upon execution.

Item 6. *Exhibits*

(A) Exhibits

Exhibit No.	Description of Exhibit
3.1 (i)	Restated Certificate of Incorporation of the Company. (1)
3.1 (ii)	Restated By-Laws of the Company. (1)
4.1	Form of certificate representing shares of Common Stock, \$0.1 par value per share. (2)
10.1	Third Amendment to Lease between the Company and ProLogis North American Properties Fund I LLC, dated August 24, 2005, with respect to the Company's distribution center.
31.1	Certification Required Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification Required Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification Required Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification Required Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(1) Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 4, 1998 (Commission File No. 0-23633).

(2) Incorporated by reference to the same numbered exhibit to the Company's
Registration Statement on Form S-1 (Registration No. 333-41055).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

1-800 CONTACTS, INC.

Dated: November 10, 2005

By: /s/ Jonathan C. Coon
Name: Jonathan C. Coon
Title: Chief Executive Officer

By: /s/ Brian W. Bethers
Name: Brian W. Bethers
Title: President and Chief Financial Officer